OUR FOCUS
Powerful Biology. Novel Medicines. Transformative Impact.
IN THE NEWS
NGM Discloses Third Oncology Development Candidate, NGM438, a Novel Antagonist Antibody Inhibiting LAIR1 for the Treatment of Advanced Solid Tumors
Powerful Biology. Novel Medicines. Transformative Impact.
PIPELINE HIGHLIGHT
NGM707's potential: improve patient immune responses to tumors by inhibiting both the ILT2 and ILT4 receptors
ILT2 and ILT4 may serve as checkpoints that enable tumors to evade immune detection.
Powerful Biology. Novel Medicines. Transformative Impact.
PIPELINE HIGHLIGHT
Aldafermin's potential: reverse fibrosis and resolve non-alcoholic steatohepatitis (NASH)
NASH is a serious liver disease affecting millions of people ... and growing.
Powerful Biology. Novel Medicines. Transformative Impact.
PIPELINE HIGHLIGHT
NGM621's potential: reducing disease progression in geographic atrophy (GA)
GA is a progressive retinal degenerative disease
impacting over 5 million people worldwide.
Powerful Biology. Novel Medicines. Transformative Impact.
BECOME AN NGMer
We love working together and challenging each other to pursue great science that will deliver a big impact for patients.
Curious, creative and driven to make a difference?
Consider NGM to advance your career!
OUR PIPELINE
We aspire to operate one of the most productive R&D engines in the biopharma industry.
Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.
We have built our company around core scientific values that frame our approach to drug discovery and development.
Our Core ValuesLatest News
Aldafermin for NASH
Significantly improving liver steatosis, inflammation, and fibrosis.
Our lead product, aldafermin (formerly NGM282), is a first-in-class, engineered variant of the human hormone FGF19 that has demonstrated a rapid regression of liver fibrosis and improvement in liver function by targeting multiple pathogenic pathways of NASH.
MORE ABOUT ALDAFERMIN
Working Here
Our People Are Our Platform.
What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence.
Join Us